Skip to main content

Table 2 Univariate and multivariate Cox proportional hazards analyses of ASCVD events after PSM

From: Immune checkpoint inhibitors in cancer: the increased risk of atherosclerotic cardiovascular disease events and progression of coronary artery calcium

Parameter

Univariate analysis

Multivariate analysis

 

Hazard ratio (95% CI)

p-value

Hazard ratio (95% CI)

p-value

ICIs

 No

Reference

   

 Yes

5.166 (1.969, 13.553)

 < 0.001

5.104 (1.942, 13.416)

 < 0.001

Sex

 Female

Reference

   

 Male

0.602 (0.245, 1.477)

0.268

  

Age

 < 65

Reference

   

 ≥ 65

1.775 (0.847, 3.718)

0.128

  

Body mass index (kg/m2)

0.942 (0.830, 1.069)

0.353

  

Hypertension

 No

Reference

   

 Yes

1.580 (0.759, 3.279)

0.221

  

Diabetes

 No

Reference

   

 Yes

0.819 (0.195, 3.446)

0.786

  

Smoking index

 ≤ 400

Reference

   

 > 400

2.066 (0.993, 2.292)

0.052

1.709 (0.810, 3.610)

0.159

Hyperlipidemia

 No

Reference

   

 Yes

0.957 (0.333, 2.751)

0.936

  

History of cardiovascular disease

 No

Reference

   

 Yes

2.981 (1.273, 6.983)

0.012

2.801 (1.176, 6.671)

0.020

Stages

 Stage III

Reference

   

 Stage IV

1.511 (0.632, 3.610)

0.354

  

Chest radiation therapy

 No

Reference

   

 Yes

1.580 (0.719, 3.471)

0.254

  

Statins

 No

Reference

   

 Yes

0.931 (0.221, 3.921)

0.923

  

Aspirin

 No

Reference

   

 Yes

2.564 (0.776, 8.477)

0.123

  

Hemoglobin (g/L)

1.000 (0.979, 1.022)

0.997

  

Neutrophil-to-lymphocyte ratio

1.013 (0.961, 1.068)

0.632

  

Platelet count-to-lymphocyte ratio

1.000 (0.997, 1.002)

0.763

  
  1. All hazard ratios are shown for one-unit increments for each variable except for categorical variables
  2. Abbreviations: ASCVD atherosclerotic cardiovascular disease, ICI immune checkpoint inhibitor, CI confidence interval, PSM propensity score matching